The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Repopulation of cancer cells during therapy: an important cause of treatment failure
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The hazard of accelerated tumor clonogen repopulation during radiotherapy
Withers, H. R., Taylor, J. M. G., & Maciejewski, B. (1988) · Acta Oncologica · doi:10.3109/02841868809090333 · Cited by 1,601
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., & Ariyoshi, Y. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2692 · Cited by 1,495
Fu, K. K., Pajak, T. F., Trotti, A., Jones, C. U., Spencer, S. A., Phillips, T. L., Garden, A. S., Ridge, J. A., Cooper, J. S., & Ang, K. K. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00663-5 · Cited by 1,357
Ang, K. K., Berkey, B. A., Tu, X., Zhang, H. Z., Katz, R. L., Hammond, E. H., Fu, K. K., & Milas, L. (2002) · PubMed · Cited by 1,198
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,113
Eifel, P. J., Winter, K., Morris, M., Levenback, C., Grigsby, P. W., Cooper, J., Rotman, M., Gershenson, D., & Mutch, D. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.197 · Cited by 1,018
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Tannock, I. F. (1968) · British Journal of Cancer · doi:10.1038/bjc.1968.34 · Cited by 763
Self-citation
Cited by
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Self-citationAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Self-citationCancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2013 · Cited by 1,699
Strategies to improve radiotherapy with targeted drugs
Begg, A. C., Stewart, F. A., & Vens, C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3007 · Cited by 1,118
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793
Gunderson, L. L., Winter, K. A., Ajani, J. A., Pedersen, J. E., Moughan, J., Benson, A. B., Thomas, C. R., Mayer, R. J., Haddock, M. G., Rich, T. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.8085 · Cited by 588
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance
Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E., Ho, P. L., et al. (2015) · Nature · doi:10.1038/nature14034 · Cited by 578
The Linear-Quadratic Model Is Inappropriate to Model High Dose per Fraction Effects in Radiosurgery
Kirkpatrick, J. P., Meyer, J. J., & Marks, L. B. (2008) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.04.005 · Cited by 516
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499
Self-citationAntiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Kerbel, R. S. (2006) · Science · doi:10.1126/science.1125950 · Cited by 466
The concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 443
Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties
Levina, V., Marrangoni, A. M., DeMarco, R., Gorelik, E., & Lokshin, A. E. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003077 · Cited by 407
Innovations in image-guided radiotherapy
Verellen, D., Ridder, M. D., Linthout, N., Tournel, K., Soete, G., & Storme, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2288 · Cited by 384
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J.-C., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 362
Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., Freeman, M. L., & Arteaga, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30740 · Cited by 346
Clinical development of new drug–radiotherapy combinations
on behalf of the NCRI CTRad Academia-Pharma Joint Working Group, Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.79 · Cited by 320
Metronomics: towards personalized chemotherapy?
André, N., Carré, M., & Pasquier, E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.89 · Cited by 320
Chemotherapy and Dietary Phytochemical Agents
Sak, K. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/282570 · Cited by 310
Molecular Imaging–Based Dose Painting: A Novel Paradigm for Radiation Therapy Prescription
Bentzen, S. M., & Gregoire, V. (2011) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.10.001 · Cited by 307
Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M. B., AOCS Study Group, et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1564 · Cited by 302
Drug rechallenge and treatment beyond progression—implications for drug resistance
Kuczynski, E. A., Sargent, D. J., Grothey, A., & Kerbel, R. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.158 · Cited by 286
Cancer stem cells and radioresistance
Rycaj, K., & Tang, D. G. (2014) · International Journal of Radiation Biology · doi:10.3109/09553002.2014.892227 · Cited by 254
Zhang, X., Fryknäs, M., Hernlund, E., Fayad, W., De Milito, A., Olofsson, M. H., Gogvadze, V., Dang, L., Påhlman, S., Schughart, L. A. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms4295 · Cited by 253
Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance
Liu, S.-C., Tsang, N.-M., Chiang, W.-C., Chang, K.-P., Hsueh, C., Liang, Y., Juang, J.-L., Chow, K.-P. N., & Chang, Y.-S. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63428 · Cited by 184
Bent, E. H., Gilbert, L. A., & Hemann, M. T. (2016) · Genes & Development · doi:10.1101/gad.284851.116 · Cited by 179
Levina, V., Marrangoni, A., Wang, T., Parikh, S., Su, Y., Herberman, R., Lokshin, A., & Gorelik, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1102 · Cited by 155
Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1852-8 · Cited by 113
“The faster tumor regrowth kinetics that we observed with doxorubicin, cisplatin, irinotecan, and gemcitabine may be due to the selective sparing of stem cells in the hypoxic regions of xenografts [22, 39].”
Crawford, S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00068 · Cited by 108
Jia, D., Li, L., Andrew, S., Allan, D., Li, X., Lee, J., Ji, G., Yao, Z., Gadde, S., Figeys, D., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.319 · Cited by 105
Zimmerman, M. A., Huang, Q., Li, F., Liu, X., & Li, C.-Y. (2013) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.05.003 · Cited by 59
Yonucu, S., Yιlmaz, D., Phipps, C., Unlu, M. B., & Kohandel, M. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005724 · Cited by 46
Host effects contributing to cancer therapy resistance.
Katz, O. B., & Shaked, Y. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.002 · Cited by 47
Cancer Cells Enter an Adaptive Persistence to Survive Radiotherapy and Repopulate Tumor
Zhao, Y., Lu, T., Song, Y., Wen, Y., Deng, Z., Fan, J., Zhao, M., Zhao, R., Luo, Y., xie, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202204177 · Cited by 29
Metadata
- Authors
- Kim, J. J., & Tannock, I. F.
- Venue
- Nature Reviews Cancer
- Published
- 2005-06-20
- Volume
- 5
- Issue
- 7
- Pages
- 516-525
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1977127004
- Cited by
- 686
- References
- 68
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.